NASDAQ:TORCresTORbio Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding resTORbio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.10 +0.07 (+3.45 %) (As of 05/25/2020 04:00 PM ET) Add Compare Share Today's Range$1.91Now: $2.10▼$2.1350-Day Range$1.02MA: $1.48▼$2.1052-Week Range$0.86Now: $2.10▼$11.96Volume1.15 million shsAverage Volume1.31 million shsMarket Capitalization$76.54 millionP/E RatioN/ADividend YieldN/ABeta2.42 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.1 Analyst's Opinion Consensus RatingresTORbio has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.67, resTORbio has a potential upside of 455.6% from its current price of $2.10.Amount of Analyst CoverageresTORbio has only been the subject of 1 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesresTORbio has received 138 “outperform” votes. (Add your “outperform” vote.)Underperform VotesresTORbio has received 136 “underperform” votes. (Add your “underperform” vote.)Community SentimentresTORbio has received 50.36% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about resTORbio and other stocks. Vote “Outperform” if you believe TORC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TORC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldresTORbio does not currently pay a dividend.Dividend GrowthresTORbio does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, resTORbio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 11.80% of the stock of resTORbio is held by insiders.Percentage Held by Institutions36.32% of the stock of resTORbio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for resTORbio are expected to grow in the coming year, from ($1.24) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of resTORbio is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of resTORbio is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioresTORbio has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.1Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.57 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TORC Previous Symbol CUSIPN/A CIK1720580 Webwww.restorbio.com Phone857-315-5528Debt Debt-to-Equity RatioN/A Current Ratio30.25 Quick Ratio30.25Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.24 per share Price / Book0.94Profitability EPS (Most Recent Fiscal Year)($2.41) Net Income$-82,740,000.00 Net MarginsN/A Return on Equity-79.90% Return on Assets-73.09%Miscellaneous EmployeesN/A Outstanding Shares36,446,000Market Cap$76.54 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable NASDAQ:TORC Rates by TradingView Receive TORC News and Ratings via Email Sign-up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter. resTORbio (NASDAQ:TORC) Frequently Asked Questions How has resTORbio's stock been impacted by COVID-19 (Coronavirus)? resTORbio's stock was trading at $1.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TORC stock has increased by 79.5% and is now trading at $2.10. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of resTORbio? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for resTORbio in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for resTORbio. When is resTORbio's next earnings date? resTORbio is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for resTORbio. How were resTORbio's earnings last quarter? resTORbio, Inc. (NASDAQ:TORC) released its quarterly earnings results on Thursday, May, 7th. The company reported ($0.19) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.34) by $0.15. View resTORbio's earnings history. What price target have analysts set for TORC? 5 Wall Street analysts have issued 1-year target prices for resTORbio's shares. Their forecasts range from $3.00 to $28.00. On average, they expect resTORbio's stock price to reach $11.67 in the next year. This suggests a possible upside of 455.6% from the stock's current price. View analysts' price targets for resTORbio. Has resTORbio been receiving favorable news coverage? Media coverage about TORC stock has trended somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. resTORbio earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutresTORbio. Are investors shorting resTORbio? resTORbio saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 726,400 shares, a decrease of 28.1% from the April 30th total of 1,010,000 shares. Based on an average trading volume of 1,100,000 shares, the short-interest ratio is presently 0.7 days. Approximately 3.4% of the shares of the company are short sold. View resTORbio's Current Options Chain. Who are some of resTORbio's key competitors? Some companies that are related to resTORbio include Menlo Therapeutics (MNLO), Verastem (VSTM), Concert Pharmaceuticals (CNCE), Avid Bioservices (CDMO), Lannett (LCI), Neptune Wellness Solutions (NEPT), OrganiGram (OGI), Galera Therapeutics (GRTX), Chiasma (CHMA), Verrica Pharmaceuticals (VRCA), Mallinckrodt (MNK), Bicycle Therapeutics (BCYC), AMAG Pharmaceuticals (AMAG), Abeona Therapeutics (ABEO) and Urovant Sciences (UROV). View all competitors. What other stocks do shareholders of resTORbio own? Based on aggregate information from My MarketBeat watchlists, some companies that other resTORbio investors own include SCYNEXIS (SCYX), Abeona Therapeutics (ABEO), Novavax (NVAX), Spectrum Pharmaceuticals (SPPI), Viking Therapeutics (VKTX), Catalyst Pharmaceuticals (CPRX), Denali Therapeutics (DNLI), Opko Health (OPK), VBI Vaccines (VBIV) and Agile Therapeutics (AGRX). Who are resTORbio's key executives? resTORbio's management team includes the following people: Mr. Chen Schor, Co-Founder, Pres, CEO & Director (Age 47)Dr. Joan Mannick M.D., Co-Founder & Chief Medical Officer (Age 60)Mr. John J. McCabe CPA, CPA, VP of Fin. (Age 51)Ms. Jennifer Robinson, Sr. Director of Investor Relations & Corp. CommunicationDr. Abdellah Sentissi Ph.D., Head of CMC & Pharmaceutical Devel. (Age 69) When did resTORbio IPO? (TORC) raised $86 million in an initial public offering on Friday, January 26th 2018. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is resTORbio's stock symbol? resTORbio trades on the NASDAQ under the ticker symbol "TORC." Who are resTORbio's major shareholders? resTORbio's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.34%), Acadian Asset Management LLC (2.58%), Morgan Stanley (2.31%), Geode Capital Management LLC (0.95%), State Street Corp (0.87%) and Two Sigma Investments LP (0.80%). View institutional ownership trends for resTORbio. Which major investors are selling resTORbio stock? TORC stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, State Street Corp, and JPMorgan Chase & Co.. View insider buying and selling activity for resTORbio. Which major investors are buying resTORbio stock? TORC stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Two Sigma Advisers LP, Russell Investments Group Ltd., Two Sigma Investments LP, Alambic Investment Management L.P., BlackRock Inc., Wells Fargo & Company MN, and Bank of New York Mellon Corp. View insider buying and selling activity for resTORbio. How do I buy shares of resTORbio? Shares of TORC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is resTORbio's stock price today? One share of TORC stock can currently be purchased for approximately $2.10. How big of a company is resTORbio? resTORbio has a market capitalization of $76.54 million. The company earns $-82,740,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. What is resTORbio's official website? The official website for resTORbio is www.restorbio.com. How can I contact resTORbio? resTORbio's mailing address is 500 BOYLSTON STREET 13TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-315-5528. This page was last updated on 5/26/2020 by MarketBeat.com Staff
